>>1
イベルメクチンにおけるメタアナリシス
https://ivmmeta.com

Studies Prophylaxis Early treatment Late treatment
All studies 75 83% [74‑89%] 66% [53‑75%] 40% [24‑53%]
Peer-reviewed 53 85% [74‑92%] 68% [50‑80%] 42% [18‑59%]
w/GMK/BBC exclusions 51 82% [68‑89%] 73% [64‑80%] 53% [29‑69%]
RCTs 32 84% [25‑96%] 62% [45‑74%] 23% [-1‑41%]
RCTs w/GMK/BBC exc. 25 84% [25‑96%] 69% [56‑77%] 26% [-2‑46%]


他薬比較

Evidence base used for other COVID-19 approvals
Medication Studies Patients Improvement
Molnupiravir (UK) 1 775 50%
Budesonide (UK) 1 1,779 17%
Remdesivir (USA EUA) 1 1,063 31%
Casirivimab/i.. (USA EUA) 1 799 66%
Ivermectin evidence 75 57,433 66% [58‑73%]